- Home
- COSM vs MYNZ Comparison
COSM vs MYNZ Comparison
Compare COSM & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COSM
- MYNZ
- Stock Information
- Founded
- COSM 2009
- MYNZ 2021
- Country
- COSM Greece
- MYNZ Germany
- Employees
- COSM N/A
- MYNZ N/A
- Industry
- COSM Other Pharmaceuticals
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- COSM Health Care
- MYNZ Health Care
- Exchange
- COSM Nasdaq
- MYNZ Nasdaq
- Market Cap
- COSM 8.2M
- MYNZ 7.2M
- IPO Year
- COSM 2013
- MYNZ 2021
- Fundamental
- Price
- COSM $0.40
- MYNZ $3.20
- Analyst Decision
- COSM
- MYNZ Buy
- Analyst Count
- COSM 0
- MYNZ 2
- Target Price
- COSM N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- COSM 334.1K
- MYNZ 105.1K
- Earning Date
- COSM 04-16-2025
- MYNZ 05-06-2025
- Dividend Yield
- COSM N/A
- MYNZ N/A
- EPS Growth
- COSM N/A
- MYNZ N/A
- EPS
- COSM N/A
- MYNZ N/A
- Revenue
- COSM $54,426,402.00
- MYNZ $893,991.00
- Revenue This Year
- COSM $28.14
- MYNZ $42.95
- Revenue Next Year
- COSM N/A
- MYNZ N/A
- P/E Ratio
- COSM N/A
- MYNZ N/A
- Revenue Growth
- COSM 1.97
- MYNZ N/A
- 52 Week Low
- COSM $0.28
- MYNZ $0.18
- 52 Week High
- COSM $1.58
- MYNZ $8.20
- Technical
- Relative Strength Index (RSI)
- COSM 48.76
- MYNZ 40.90
- Support Level
- COSM $0.28
- MYNZ $3.03
- Resistance Level
- COSM $0.39
- MYNZ $3.31
- Average True Range (ATR)
- COSM 0.05
- MYNZ 0.35
- MACD
- COSM 0.01
- MYNZ 0.06
- Stochastic Oscillator
- COSM 71.45
- MYNZ 61.80
About COSM Cosmos Health Inc.
Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.